We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Real-Time fMRI Helps Treat Tourette Syndrome

By HospiMedica International staff writers
Posted on 12 Sep 2019
Adolescents with Tourette Syndrome (TS) can control their facial tics through an imaging technique that allows them to monitor the function of their own brain in real time.

Researchers at Yale School of Medicine (New Haven, CT, USA) conducted a randomized, sham-controlled trial in 21 adolescents with TS to examine if real-time functional magnetic resonance imaging (fMRI) neurofeedback could help reduce activity in the supplementary motor area (SMA), which has been shown to be responsible for TS tics. More...
The primary outcome measure of tic severity was the Yale Global Tic Symptom Severity Scale (YGTSS), with the secondary outcome being control over the SMA, as assessed in neuroimaging scans.

The study subjects were tasked with alternately raising and lowering activity in the SMA, which was displayed as a real-time graph during brain imaging scans. The results showed that participants had a significant 3.8-point difference in tic reduction on the YGTSS scale after neurofeedback, as compared to sham. However, there were no differences in changes on the secondary measure of control over the SMA. The study was published on August 13, 2019, in the Journal of Biological Psychiatry.

“Currently available treatments for tics in Tourette Syndrome include behavior therapy and pharmaceuticals, but not everyone responds. This is the first study of its kind showing that real-time fMRI neurofeedback has potential as a treatment,” said lead author Denis Sukhodolsky, PhD, of the Yale Child Study Center. “However, no effects were found in terms of change in control over the SMA, the hypothesized mechanism of action.”

TS is a neurological disorder characterized by repetitive, stereotyped, involuntary movements and vocalizations called tics. The disorder is named after Dr. Georges Gilles de la Tourette, the pioneering French neurologist who in 1885 first described the condition in an 86-year-old French noblewoman. The early symptoms are typically noticed first in childhood, with average onset between the ages of three and nine. Although TS symptoms may last a lifetime, most people with the condition experience their worst tic symptoms in their early teens, with improvement occurring in the late teens and continuing into adulthood.

Related Links:
Yale School of Medicine


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Radiofrequency Generator
GX1
Tourniquet System
heidi– mein Tourniquet
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Business

view channel
Image: Sempresto’s Smartphone-Integrated Epinephrine Auto-Injector Wins Red Dot Design Award (Photo courtesy of Sempresto)

Smartphone-Integrated Epinephrine Auto-Injector Concept Wins Red Dot Design Award

Severe allergic reactions can escalate rapidly and require prompt epinephrine, yet many at-risk patients do not consistently carry their auto-injector. With food allergies affecting an estimated 220 million... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.